ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CLPT / forecast
MOBI (50) EMBC (68) OFIX (42) SI (44) ⌘ Pro Terminal →

ClearPoint Neuro Inc. (CLPT) 12-Month Stock Forecast & Price Target Cone

$10.67 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.65

ClearPoint Neuro Inc. (CLPT) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $342.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLPT compare to MOBI and EMBC in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLPT?
▼

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.65 (-0.22%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (5)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
$21 Bull$9 Base$7 Bear
📬 FREE CLPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLPT)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY CLPT SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (32% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$9.81-3.7% Next Q
Q2 (-2Q)
16
Grade E$9.45+2.5% Next Q
Q3 (-1Q)
18
Grade E$9.69+10.1% Next Q
Current
19
Grade E$10.67-12% Hist 90D α
Trajectory: E (15) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLPT currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.32) and Max Pain ($11.20) forces dealer call-delta covering toward $20.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CLPT Position Size: $10,000

Shares at $10.67: 937.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $6.86
$6,429
$-3,571 (-35.7%)
12M Consensus BaseTarget $8.80
$8,247
$-1,753 (-17.5%)
12M Bull Case BreakoutTarget $20.66
$19,363
+$9,363 (+93.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$974%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1969%B
JP MorganUS Large-Cap ResearchSELL$858%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLPT)

  • ✓Walkthrough of CLPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.56%▼ DESCENDING CHANNEL
2026-11-03O $10.69H $10.69L $10.67C $10.67VOL 916.6K
RES: $14.89SUP: $8.80SMA50: $12.32SMA200: $12.92
$20.38$17.27$14.16$11.05$7.95RES $14.89SUP $8.80$10.672026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLPT Butterfly Map → + Track CLPT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +17.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLPT)

Health Care Rank #994 of 1016 ⚔️ MOBI vs CLPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLPT vs. MOBI, EMBC, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ClearPoint Neuro Inc. (CLPT) ranks #994 by composite RQD confidence (19/100, grade E) and #500 by equity capitalization ($342.0M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with CLPT at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLPT ACTIVE
ClearPoint Neuro Inc.
E 19/100 — 61.4% -35.0% -0.19% $342.0M Benchmark Subject
MOBI
Mobia Medical Inc.
D 50/100 — — — -6.12% $352.2M /mobi-vs-clpt →
EMBC
Embecta Corp.
C+ 68/100 3.9x 62.6% 35.5% -4.73% $354.1M /embc-vs-clpt →
OFIX
Orthofix Medical Inc.
D- 42/100 — 68.8% -12.2% -11.43% $369.4M /ofix-vs-clpt →
SI
Shoulder Innovations Inc.
D 44/100 — 76.5% -16.1% -6.41% $398.3M /si-vs-clpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285550

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported GAAP revenue of $37.0M (+17.8% vs. FY2024 revenue of $31.4M , and +54.3% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of -$23.9M, and free cash flow of -$24.4M (-164.7% YoY). On the balance sheet, CLPT closed FY2025 with $97.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $37.0M -$25.5M -$23.9M -$24.4M $97.7M —
FY2024 (FY) 2024-12-31 $31.4M -$18.9M -$8.9M -$9.2M $39.2M —
FY2023 (FY) 2023-12-31 $24.0M -$22.1M -$13.7M -$13.7M — —

3. CLPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

How does CLPT compare to MOBI and EMBC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLPT?

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLPT trading relative to its 50-day, 200-day, and 52-week technical levels?

CLPT last traded at $10.67 (-0.19% on volume of 916,551 shares), positioning the stock -13.39% below its 50-day simple moving average ($12.32) and -17.41% below its 200-day simple moving average ($12.92). Across its 52-week range of $8.27 to $19.68, CLPT sits at the 21.0% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($9.47 to $11.87).

CLPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CLPT's 12-month stock price target?

ClearPoint Neuro Inc. (CLPT) carries a 12-month consensus base price target of $8.8 (-17.5% from $10.67), with a bull-case target of $20.66 and a bear-case floor of $6.86.

Is CLPT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CLPT E (Strong Sell — SELL) with an RQD Confidence score of 19/100.

Direct Sub-Reports: CLPT RQD Cockpit CLPT 12M Forecast CLPT Earnings & Move CLPT Dividends & DRIP CLPT Insiders & 13F CLPT Whale Options CLPT Profit Sankey CLPT News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLPT — ClearPoint Neuro Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CLPT scores 19 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 2 / 20 (ROIC -35%; FCF yield -7.13%), indicating the business is not currently generating returns on capital or positive free cash flow. The Whale 13F Flow pillar scores 5 / 20 for institutional accumulation and options positioning, the Insider Conviction pillar scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, and the Macro Regime Fit pillar scores 3 / 20 (Beta 1.0; sector sensitivity). The Forensic Balance Sheet pillar scores 6 / 20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5), which is the weakest structural signal in the financial-distress assessment. For a prospective investor, the upside case rests on the reported gross margin of 61.4% and the revenue growth shown across FY 2023 to FY 2025, but the rating places more weight on negative operating economics, low Altman Z-Score reading, and weak insider and institutional support. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data; the stock's positioning within its $8.27 - $24.75 52-week range and $342.7M market capitalization should be read against these forensic signals. This analysis is educational and not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$37.0M$-24.2M$-25.5MN/A$-24.4M$45.9MN/A
FY 2024$31.4M$-19.7M$-18.9MN/A$-9.2M$20.1MN/A
FY 2023$24.0M$-22.4M$-22.1MN/A$-13.7MN/AN/A

Per the SEC financials, operating and net losses persisted across all three reported periods, with operating margin at -60% and net margin at -60% per the market data section. Gross margin is reported at 61.4%. ROIC is -35% per the market data section and the Roarable RQD rating. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9 per the Forensic Balance Sheet pillar. Debt/Equity is 0.5 per the same pillar, while debt values in the SEC financials are N/A.

Recent Catalysts & News Wire Analysis

  • RISK WATCH (RED): A Yahoo Finance report headlined that CLPT reported a Q3 loss and missed revenue estimates.
  • MARKET WIRE (YELLOW): A www.debelegger.nl report carried a general stock price and chart headline.
  • CATALYST (GREEN): A GuruFocus report headlined revenue growth in Q3 and a reference to a gene-related item.
  • MARKET WIRE (YELLOW): A Benzinga report carried the Q3 2026 earnings call transcript headline.
  • RISK WATCH (RED): A Simply Wall St report headlined cash runway and loss pressure.
  • RISK WATCH (RED): A Pluang report headlined a lawsuit probing CLPT over a stock drop following a Huntington's drug trial setback.

The Butterfly Supply-Chain Graph reports sector Health Care, industry Medical/Dental Instruments, supply chain NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the FY 2025 debt balances, given that debt is reported as N/A across all periods?
  • What EPS, P/E, and EV/EBITDA figures apply, since these are not available in source data?
  • What is the outcome of the lawsuit referenced in the Pluang report, and what is its potential financial exposure?
  • What is the company's cash runway given the FY 2025 FCF of $-24.4M against $45.9M cash?
  • What drove the FY 2025 revenue increase and does it reflect durable demand?

CLPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ClearPoint Neuro Inc. (CLPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLPT Bull vs. Bear Conversation Board — What's Your Call at $10.67?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLPT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CLPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.41 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLPT (E • RQD 19/100) a Buy at $10.69?

Welcome to the CLPT (ClearPoint Neuro Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.77 (-18.0%)
Spot @ $10.69

Pump the brakes on CLPT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLPT, but look at what you are paying: current EV/EBITDA multiples with 61.4% gross margins. Unless ClearPoint Neuro Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.47 (+26.0%)
Spot @ $10.69

CLPT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLPT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $10.69 (52-wk range $8.27 - $24.75), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%